This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%

1 hour ago 2

Jonathan Ponciano, The Motley Fool

Sat, May 23, 2026 astatine 3:37 PM CDT 4 min read

On May 15, 2026, Prosight Management disclosed a acquisition of 468,463 shares of GeneDx Holdings (NASDAQ:WGS), an estimated $42.72 cardinal commercialized based connected quarterly mean pricing.

What happened

According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Prosight Management accrued its holdings successful GeneDx Holdings by 468,463 shares. The estimated transaction value, based connected the mean unadjusted closing terms for the archetypal 4th of 2026, was $42.72 million. The quarter-end worth of the position, reflecting some terms alteration and stock addition, accrued by $26.46 cardinal to $33.62 million.

What other to cognize

The presumption present comprises astir 5.51% of Prosight's 13F reportable assets nether management.
Top 5 holdings aft the filing:
- NASDAQ: NKTR: $52.88 cardinal (8.7% of AUM)
- NASDAQ: JANX: $49.34 cardinal (8.1% of AUM)
- NASDAQ: PRCT: $48.64 cardinal (8.0% of AUM)
- NYSE: BSX: $49.92 cardinal (8.2% of AUM))
- NASDAQ: LKFT: $46.50 cardinal (7.6% of AUM)
As of Friday, GeneDx shares were priced astatine $47.31, down 30% implicit the past twelvemonth and good underperforming the S&P 500, which is alternatively up astir 28% successful the aforesaid period.

Company overview

Metric

Value

Price (as of Friday)	$47.31
Market Capitalization	$1.4 billion
Revenue (TTM)	$442.68 million
Net Income (TTM)	($77.81 million)

Company snapshot

GeneDx Holdings Corp. provides wellness quality solutions, leveraging AI and instrumentality learning to analyse objective and genomic information done its Centrellis platform.
The institution operates successful the healthcare accusation services sector, focusing connected integrating AI-driven analytics into objective and genomic data.
GeneDx's strategy centers connected enabling precision medicine and individualized wellness trajectories done proprietary exertion platforms.

GeneDx Holdings Corp. aims to present actionable, science-based insights to healthcare providers, supporting improved outcomes and much informed aesculapian decision-making. Its competitory borderline lies successful its quality to alteration precision medicine done precocious information analytics.

What this transaction means for investors

Prosight’s determination is notable fixed GeneDx stock's crisp diminution implicit the past year, but nether the hood, determination are reasons wherefore a money mightiness beryllium bullish, and the archetypal 4th offered grounds for that thesis. Revenue climbed 17% twelvemonth implicit twelvemonth to $102.3 million, portion exome and genome investigating gross accrued 27%, and investigating measurement jumped 34% to 27,488 tests. Perhaps astir importantly, absorption inactive expects astatine slightest 30% exome and genome measurement maturation this year, and it maintained its anticipation for astir 70% adjusted gross margins.

On the different hand, GeneDx lowered its full-year gross outlook to $475 cardinal to $490 cardinal from a anterior scope of $540 cardinal to $555 million. But the institution continues to put successful expanding entree to testing, adding Medicaid sum successful aggregate states, and launching caller products designed to summation adoption.

For semipermanent investors, the cardinal question is whether GeneDx tin crook its rapidly increasing genomic database and AI-driven diagnostics level into durable profitability. Prosight's acquisition suggests it believes the reply is yes, and that the marketplace whitethorn beryllium underestimating however invaluable that information plus could go if precision medicine continues moving into the mainstream.

Read Entire Article